Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2018

  • ID: 4457555
  • Report
  • 125 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • A1M Pharma AB
  • Am-Pharma BV
  • Arch Biopartners Inc
  • CFM Pharma Holding BV
  • DURECT Corp
  • G1 Therapeutics Inc
  • MORE
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2018, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 4, 21, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • A1M Pharma AB
  • Am-Pharma BV
  • Arch Biopartners Inc
  • CFM Pharma Holding BV
  • DURECT Corp
  • G1 Therapeutics Inc
  • MORE
Introduction

Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview

Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development

A1M Pharma AB

Alloksys Life Sciences BV

Am-Pharma BV

Angion Biomedica Corp

Arch Biopartners Inc

Cellmid Ltd

CFM Pharma Holding BV

Cypralis Ltd

DURECT Corp

Evotec AG

Exponential Biotherapies Inc

G1 Therapeutics Inc

Kringle Pharma Inc

Mitotech SA

Quark Pharmaceuticals Inc

SBI Pharmaceuticals Co Ltd

Silver Creek Pharmaceuticals Inc

Spherium Biomed SL

STATegics Inc

Stealth BioTherapeutics Inc

Torrent Pharmaceuticals Ltd

Xigen SA

Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles

(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile

ANG-4102 - Drug Profile

BB-3 - Drug Profile

brimapitide - Drug Profile

CAB-101 - Drug Profile

CC-4066 - Drug Profile

cilastatin - Drug Profile

Drug for Kidney Diseases - Drug Profile

DUR-928 - Drug Profile

EA-230 - Drug Profile

elamipretide - Drug Profile

G-1T100182 - Drug Profile

IL-233 - Drug Profile

iron sucrose + Sn protoporphyrin - Drug Profile

K-1052 - Drug Profile

KP-100IT - Drug Profile

Metablok - Drug Profile

MG-53 - Drug Profile

NOXD-21 - Drug Profile

NYK-1341 - Drug Profile

Plastomitin - Drug Profile

QPI-1002 - Drug Profile

R-190 - Drug Profile

Recombinant Alkaline Phosphatase Enzyme Replacement for Acute Kidney Injury - Drug Profile

Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile

Recombinant Klotho Replacement for Kidney Disease, Aging, Breast Cancer, Cognitive Impairment and Type 2 Diabetes - Drug Profile

Recombinant Peptides to Agonize renalase for Acute Pancreatitis, Acute Kidney Injury and Cisplatin Induced Kidney Injury - Drug Profile

Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile

RLS-003 - Drug Profile

RMC-035 - Drug Profile

SGF-1 - Drug Profile

Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile

Small Molecule to Inhibit PADI4 for Acute Kidney Injury, Hepatic and Pancreatic Injuries - Drug Profile

STSE-15 - Drug Profile

SUL-138 - Drug Profile

TRC-160334 - Drug Profile

TTX-332 - Drug Profile

Vanadis-03 - Drug Profile

Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects

Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products

Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Alloksys Life Sciences BV, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma BV, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Arch Biopartners Inc, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Ltd, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by CFM Pharma Holding BV, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cypralis Ltd, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corp, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Evotec AG, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Exponential Biotherapies Inc, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics Inc, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma Inc, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mitotech SA, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals Inc, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by SBI Pharmaceuticals Co Ltd, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Silver Creek Pharmaceuticals Inc, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Spherium Biomed SL, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics Inc, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Stealth BioTherapeutics Inc, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Ltd, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Xigen SA, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1

Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H1

List of Figures

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1

Number of Products under Development by Companies, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • A1M Pharma AB
  • Alloksys Life Sciences BV
  • Am-Pharma BV
  • Angion Biomedica Corp
  • Arch Biopartners Inc
  • Cellmid Ltd
  • CFM Pharma Holding BV
  • Cypralis Ltd
  • DURECT Corp
  • Evotec AG
  • Exponential Biotherapies Inc
  • G1 Therapeutics Inc
  • Kringle Pharma Inc
  • Mitotech SA
  • Quark Pharmaceuticals Inc
  • SBI Pharmaceuticals Co Ltd
  • Silver Creek Pharmaceuticals Inc
  • Spherium Biomed SL
  • STATegics Inc
  • Stealth BioTherapeutics Inc
  • Torrent Pharmaceuticals Ltd
  • Xigen SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll